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Introduction
The recurrence rate of multinodular goiter (a thyroid
gland that is enlarged and contains multiple thyroid
nodules) varies between 8.9% and 40% [1-4]. The
main cause of recurrence is the insufficient extent of
thyroidectomy (excision of thyroid gland) during the
primary operation, which should consist of excision of
both lobes together with the isthmus and pyramidal
lobe [5-8]. The second factor which can lead to recur-
rence is the lack of substitution therapy with L-thyrox-
ine (levothyroxine) after primary operation [13,15-18].
But the recurrences occur even if total thyroidectomy
is performed, with subsequent therapy with L-thyrox-
ine. Some thyroid cells which were left during the first
operation are no longer subject to control within the
classical hypothalamic-pituitary-thyroid axis and their
growth depends on individual expression of goitro-
genic insulin-like growth factors (IGFs) and their
binding proteins (IGFBPs) [22]. Nodules in recurrent
goiters are mainly polyclonal, with a higher than usual
growth potential accelerated by unknown factors, so
the recurrence occurs not only from nodules left dur-
ing the primary operation [23-25].
It has been scientifically proven that thyroid follic-
ular cells replicate only five times [26]. In response to
appropriate stimulus, which is usually iodine deficien-
cy, the thyroid cells replicate very fast and it leads to
hyperplasia of thyroid gland. The hyperplastic goiter
grows and it can then change into colloid and cystic
goiter or become neoplastic. Apart from iodine defi-
ciency and action of TSH, other mitogenic agents
responsible for hyperplasia produced by fibroblasts,
endothelial cells, macrophages and lymphocytes have
been proposed. In every case the other factors are
responsible for specific changes. In colloid goiter the
nodules are produced as a defect of intraluminal thy-
roglobulin reabsorption. Cystic nodules are the result
of imbalance between angiogenesis and cell growth
leading to cell damage, necrosis and colliquation. Also
lymphatic thyroiditis may be rarely found as a nodular
thyroid disease. In thyroid malignancies several acti-
vated oncogenes have been found [27]. There are also
other factors like positive family history, young age at
presentation, bilateral disease and multinodular vs. sin-
gle nodules which have been accepted risk factors for
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goiter recurrence [28]. We should not forget about the
environmental chemicals and drugs which are goitro-
genic in humans e.g. iodine, lithium, thionamides, ani-
line and phenol derivates, polyhydroxyphenols,
flavonoids [27].
Material and methods
Tissue samples. The study group consisted of 30 patients operat-
ed due to a recurrent goiter between 2003 and 2009 in the Depart-
ment of Minimally Invasive Surgery and Proctology and in the
Department of General and Oncological Surgery, Medical
University in Wroclaw. During this period we performed 2630
thyroidectomies (Table 1). The primary operations were per-
formed between the years of 1980 and 2005. Types of primary
operations are presented in Table 1. During the secondary opera-
tion all the thyroid tissue was totally removed. The mean age of
patients with recurrent goiter was 57 years. The group included
only one man. Standard histological examination consisted of
macroscopic investigation, fixation in formalin and microscopic
examination of slides prepared with HE-staining on a glass slide.
Three examples of histological specimens are presented below
(Figs. 1, 2, 3).
Results
The mean time to recurrence was 15 years. The most
frequent histopathological finding upon the first and
second operation was struma nodosa. According to
our observations the same histopathological findings
were found in 36.6% cases after primary and second-
ary thyroidectomy (Table 1). Pseudo recurrence (the
recurrence in previously non-operated lobe) occurred
in 5 patients (Table 1). All the histopathological find-
ings and mean time to recurrence are presented in
Table 2.
Table 1. Studied group characteristics
Fig. 1. Struma nodosa, H+E (original magnification ×100).
Fig. 2. Struma colloides et cystic, H+E (original magnification
×100).
Fig. 3. Thyroiditis chronica lymphomatosa, H+E (original magni-
fication ×100).
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Discussion
Thyroidectomy was performed in 2630 patients (30
patients with recurrent goiter) between the years of
2003 and 2009 in the Department of Minimally Inva-
sive Surgery and Proctology and in the Department of
General and Oncological Surgery, Medical University
in Wroclaw. Operations on recurrent goiter comprised
1.14% of all thyroidectomies. Our study group was not
homogeneous because patients underwent the primary
surgery not necessarily in our departments.
In country's leading centers which specialize in goi-
ter surgery the percentage of recurrences does not
exceed 1%. Barczyñski noted 0.6% and Stajgis 0.8%
of recurrences in their material [2,4]. According to
some authors, evaluation of patients with recurrent
goiter may be imprecise and mistakes can occur. It is
not always known where the primary operation was
performed and how long did the patient with recurrent
goiter wait for the secondary operation.
In our material the mean time to recurrence was 15
years, the shortest one was 1 year and the longest one
was 24 years. In the material of Stajgis the time to
recurrence ranged between 0.5 and 48 years [10]. In
the whole material of Barczyñski the time to recur-
rence was between 1 and 48 years and the mean time
to recurrence was 17 years. In his own material it was
between 2 and 35 years and 14 years, respectively. He
stated that it would be very inaccurate to define the
mean time to recurrence because patients can change
the hospital for the secondary operation [11].
According to many authors, the strategy of surgical
treatment has a considerable impact on the prevention
of recurrences; significance of the range and com-
pleteness of thyroidectomy is emphasized. It is
believed that even 80% of recurrences may result from
inadequate surgical treatment. In many cases the limit-
ed completeness of surgery may result in the compli-
cations [9-12]. The excision of only one lobe with
macroscopic changes can lead to quite often observed
recurrence of goiter in non-operated lobe (pseudo
recurrence). In their own large clinical material (602
patients operated for recurrent goiter between 1955
and 1992), Skrzypek et al. found 86.6% of actual
recurrences and 13.4% of pseudo recurrences. The
mean time to actual recurrence was 12.2 years and the
mean time to pseudo recurrence was 5.8 years [12].
Because of the high proportion of pseudo recurrences
after thyroidectomy and short time of their formation,
the primary operation should be based on dissection of
isthmus, removal of pyramidal lobe and bilateral, suf-
ficiently complete excision of both lobes even if one of
the lobes does not show macroscopic lesions.
The recurrence after thyroidectomy performed for
benign multinodular goiter is always possible. All the
thyroid tissue which has macroscopic changes should be
removed because even small nodules or cysts can lead
to recurrence. Bononi et al. regard total thyroidectomy
as the most effective method to prevent recurrences.
When it is performed by an experienced surgeon the rate
of complications is not higher in comparison to subtotal
thyroidectomy and especially to excision of recurrent
goiter. The postoperative hypothyroidism can be effec-
tively treated with L-thyroxin [29].
The proponents of suppressive therapy with L-
thyroxin argue that its dose should be high enough to
prevent recurrences. According to some authors in
regions where iodine intake is high the substitution
therapy is not needed [20]. Some surgeons prescribe
L-thyroxin only after total thyroidectomy [29].
Aagaard et al. found that subtotal thyroidectomy
reduces only the thyroid mass but not the real cause
of recurrence. The remnants of tissue after thyroidec-
tomy have the structural and functional features of
pathologic tissue, which is no longer subject to con-
trol within the classical hypothalamic-pituitary-thy-
roid axis, thus substitution therapy may be ineffective
[14]. There is a group of opponents of substitution
therapy because in their hands it fails to reduce the
rate of recurrence [28,30]. They did not find higher
recurrence rate in post-thyroidectomy patients with-
out substitution therapy [1]. According to some sur-
geons recurrence of benign multinodular goiter is
unavoidable no matter what form of prophylaxis is
used, with the exception of the situation when total
thyroidectomy was performed [19].
Table 2.. The prevalence of different types of configuration of the histopatological findings during the first and second operation
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Thus, we should think about other factors which
may induce the re-growth of thyroid tissue after pri-
mary operation. It is an action and regulation at the cel-
lular level: the cells in recurrent goiter do not neces-
sarily derive from nodules left or missed during the
primary operation [27]. The histopathological findings
after primary and secondary thyroidectomy in our
material have been different in 66.6% cases and it sug-
gests that the mechanism of recurrence has not been
similar to this, which lead to the primary disease.
When a surgeon is not able to remove all the thyroid
cells during the primary operation it is very important
to develop therapies which will act on cellular level.
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